Reply
1. Iloprost (10 mcg/ 1 ml) Inhalation Solution from Nebulizer. The required quantity is 110 units.
2. Amiodarone (150 mg/ 3 ml) Ampoule. The required quantity is 865 units.
3. Digoxin (0.5 mg/ 2 ml) Ampoule. The required quantity is 375 units.
4. Betamethasone Disodium Phosphate (4 mg/ 1 ml) Solution for Injection. The required quantity is 2,360 units.
5. Cefuroxime (750 mg and 1500 mg) Powder for Solution for Injection. The required quantity is 6,525 units and 32,150 units respectively.
6. Voriconazole (200 mg) Powder for Preparation Solution for Infusion. The required quantity is 1,750 units.
7. Vincristine (1 mg/ 1 ml) Solution for Injection. The required quantity is 245 units.
8. Entecavirum (1 mg X 30 and 0.5 mg X 30) Tablets. The required quantity is 1,015 units and 1,745 units respectively.
9. Cytarabine (100 mg/ 5 ml) Solution for Injection. The required quantity is 535 units.
10. Cyclophosphamide (1 g) Powder for Preparation Solution for Injection. The required quantity is 115 units.
jgq@yangzijiang.com
jgq@yangzijiang.com
I am Justin from Yangtze River Pharmaceutical Group in China
APIs and FDF can be manufactured by our company.
We can also CMO
If you need them, please contact me by Tel., WhatsApp and Wechat: +86 15261051195
Email: jgq@yangzijiang.com
vishvesh.shaishav@gmail.com
We are focussed on developing new manufacturing technologies, including custom synthesis of new moleculepharma intermediate, catalyst, bulk drugs, pharma API, pharma chemicals, active pharmaceutical ingredients, pharmaceutical pellets,additives, contract manufacturing, chemicals. We began in the field of specialty intermediates for pharmaceutical applications and developed our own purification technologies for manufacturing highly pure intermediates. And Pharmaceutical API At a later stage, we integrated forward to manufacture finished formulations for both veterinary and human consumption. Due to our completely integrated operations in the pharmaceutical sector, we continuously learn about the quality parameters for an API based on the performance of the finished formulation in order to quality their Bioequivalence Studies.
We have established finished formulation lines in South Asian and Latin American countries. It is our vision to achieve worldwide recognition as an excellent business partner from India by providing our customers with superior quality products at highly affordable prices and following that up with reliable service consistently, thereby giving them an unparalleled experience.
Our focus lies in developing new production technologies with a keen interest in frugal innovation in order to gain a competitive edge over others. We specialize in the custom synthesis of molecules and work with many reputed companies around the world on an OEM basis.pharmaceutical pellets,Intermidiates
Our finished formulations from WHO-GMP and EU-GMP units are registered/being registered in 26 countries within Asia, Europe, North America, Latin America and Africa continents including Peru, Panama, Ecuador, Chile, Curaçao, Suriname, Haiti, Aruba, Trinidad, Tobago, Philippines, Myanmar, Laos, Malaysia, Thailand, Indonesia, Hong Kong, Vietnam, Sri Lanka, Maldives, Brunei, Nepal, China, Russia, Croatia, Venezuela and Bhutan.
vishvesh.shaishav@gmail.com
vishvesh.shaishav@gmail.com
We are focussed on developing new manufacturing technologies, including custom synthesis of new moleculepharma intermediate, catalyst, bulk drugs, pharma API, pharma chemicals, active pharmaceutical ingredients, pharmaceutical pellets,additives, contract manufacturing, chemicals. We began in the field of specialty intermediates for pharmaceutical applications and developed our own purification technologies for manufacturing highly pure intermediates. And Pharmaceutical API At a later stage, we integrated forward to manufacture finished formulations for both veterinary and human consumption. Due to our completely integrated operations in the pharmaceutical sector, we continuously learn about the quality parameters for an API based on the performance of the finished formulation in order to quality their Bioequivalence Studies.
We have established finished formulation lines in South Asian and Latin American countries. It is our vision to achieve worldwide recognition as an excellent business partner from India by providing our customers with superior quality products at highly affordable prices and following that up with reliable service consistently, thereby giving them an unparalleled experience.
Our focus lies in developing new production technologies with a keen interest in frugal innovation in order to gain a competitive edge over others. We specialize in the custom synthesis of molecules and work with many reputed companies around the world on an OEM basis.pharmaceutical pellets,Intermidiates
Our finished formulations from WHO-GMP and EU-GMP units are registered/being registered in 26 countries within Asia, Europe, North America, Latin America and Africa continents including Peru, Panama, Ecuador, Chile, Curaçao, Suriname, Haiti, Aruba, Trinidad, Tobago, Philippines, Myanmar, Laos, Malaysia, Thailand, Indonesia, Hong Kong, Vietnam, Sri Lanka, Maldives, Brunei, Nepal, China, Russia, Croatia, Venezuela and Bhutan.
vishvesh.shaishav@gmail.com
export@healthpharma.in
Dear Sir,
Greetings from Health Pharma...!!!
We can support you with your requirements. Kindly request you to send email for detailed information.
Looking forward to your positive response.
Thanks...!!!
